top of page

Publications

Co-Authored Publications

2025

Development and In Vitro Characterization of [3H]GMC-058 as Radioligand for Imaging Parkinsonian-Related Proteinopathies.  Varrone A, Sousa VC,  Mugnaini M, Biesinger S, Nordvall G, Kingston L, Guzzetti I, Elmore CS, Sunnemark D, Guarino DS, Finnema S, Schou. Cells. 2025 Jun 9;14(12):869.  (The Karolinska Institute, Abbvie, AlzeCure, AstraZeneca)

​

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies. ​Zachrisson O, Johannesson M, Söderberg L, Eriksson F, Sunnemark D, Nordström E, Björklund M, Button EB, Odergren T, Möller C, Osswald G, Fälting J. Neurotherapeutics​​​​. 2025 Nov 5:e00779.    (BioArctic)

​

​​

2024

Identification and In Vitro and In Vivo Characterization of KAC-50.1 as a Potential α-Synuclein PET Radioligand. Saturnino Guarino D, Miranda Azpiazu P, Sunnemark D, Elmore CS, Bergare J, Artelsmair M, Nordvall G, Forsberg Morén A, Jia Z, Cortes-Gonzalez M, Mach RH, Wilcox KC, Finnema S, Schou M, Varrone A. ACS Chem Neurosci​​​​ence. 2024 Nov 20;15(22):4210-4219.   (The Karolinska Institute, AstraZeneca, Abbvie)

2023

[11 C]PBB3 binding in Aβ(-) or Aβ(+) corticobasal syndrome.  Cselényi Z, Wallin J, Tjerkaski J, Bloth B, Svensson S, Nennesmo I, Sunnemark D, Jelic V, Farde L, Svenningsson P. Synapse​​​​. 2023 Jul;77(4):e22269.  (Novandi Chemistry AB, The Karoliska Institute)

2021

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.  Johannesson M, Sahlin C, Söderberg L, Basun H, Fälting J, Möller C, Zachrisson O, Sunnemark D, Svensson A, Odergren T, Lannfelt L. Mol Cell Neuroscience. 2021 Jul:114:103641.  (BioArctic)

2020

Identification and in  vitro  characterization of C05-01, a PBB3 derivative with improved affinity for  alpha-synuclein.    Miranda-Azpiazu P, Svedberg M, Higuchi M, Ono M, Jia Z, Sunnemark D, Elmore CS, Schou M, Varrone A. Brain Res. 2020 Dec 15:1749:147131. (The Karolinska Institute, AstraZeneca)

2018

Secretagogin is increased in plasma from type 2 diabetes patients and potentially reflects stress and islet dysfunction.  Hansson SF, Zhou AX, Vachet P, Eriksson JW, Pereira MJ, Skrtic S, Jongsma Wallin H, Ericsson-Dahlstrand A, Karlsson D, Ahnmark A, Sörhede Winzell M, Magnone MC, Davidsson P. PLoS One. 2018 Apr 27;13(4):e0196601.  (AstraZeneca)

2017

Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease. Gellhaar S, Sunnemark D, Eriksson H, Olson L, Galter D.  Cell Tissue Res. 2017 Sep;369(3):445-454. (The Karolinska Institute, AstraZeneca)

2014

Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. Ridderstad Wollberg A, Ericsson-Dahlstrand A, Juréus A, Ekerot P, Simon S, Nilsson M, Wiklund SJ, Berg AL, Ferm M, Sunnemark D, Johansson R.  Proc Natl Acad Sci USA. 2014 Apr 8;111(14):5409-14.  (AstraZeneca)

MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies. ​Lund H, Gustafsson E, Svensson A, Nilsson M, Berg M, Sunnemark D, von Euler G. Acta Neuropathol Commun. 2014 Feb 17:2:22. (Uppsala University, AstraZeneca)

2013

Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease. Gu GJ, Lund H, Wu D, Blokzijl A, Classon C, von Euler G, Landegren U, Sunnemark D, Kamali-Moghaddam M. Neuromolecular Medicine. 2013 Sep;15(3):458-69.  (Uppsala University, AstraZeneca)

Tau-tubulin kinase 1 expression, phosphorylation and co-localization with phospho-Ser422 tau in the Alzheimer's disease brain. Lund H, Cowburn RF, Gustafsson E, Strömberg K, Svensson A, Dahllund L, Malinowsky D, Sunnemark D. Brain Pathol. 2013 Jul;23(4):378-89. (AstraZeneca)

Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease. ​Gu GJ, Wu D, Lund H, Sunnemark D, Kvist AJ, Milner R, Eckersley S, Nilsson LN, Agerman K, Landegren U, Kamali-Moghaddam M. J Alzheimers Dis​​​​ease. 2013;33(3):699-713. (Uppsala University, AstraZeneca)

Key Research Supported by Our Platform
High-impact publications utilizing data generated by Offspring Biosciences

2024

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. Yu Y, Bogdan M, Zaeem Noman M, Parpal S, Bartolini E, Van Moer K, Kleinendorst SC, Saether KB, Trésaugues L, Silvander C, Lindström J, Simeon J, Timson MJ, Al-Hashimi H, Smith BD, Flynn DL, Alexeyenko A, Viklund J, Andersson M, Martinsson J, Pokrovskaja Tamm K, De Milito A, Janji B. Mol Oncology. 2024 Aug;18(8):1904-1922. (Sprint Biosciences)

Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. ​Johannesson M, Söderberg L, Zachrisson O, Fritz N, Kylefjord H, Gkanatsiou E, Button E, Svensson AS, Rachalski A, Nygren P, Osswald G, Lannfelt L, Möller C. Mol Cell Neurosci​​​​ence. 2024 Sep:130:103949.1  (BioArctic)

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.  Söderberg L, Johannesson M, Gkanatsiou E, Nygren P, Fritz N, Zachrisson O, Rachalski A, Svensson A‑S, Button E, Dentoni G, Osswald G, Lannfelt L, Möller C. Sci Rep. 2024 May 13;14(1):10868. (BioArctic)

Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer's disease tauopathies.  Lindberg A, Murrell E, Tong J, Mason N, Sohn D, Sandell J, Ström P, Stehouwer J, Lopresti B, Viklund J, Svensson S, Mathis C, Vasdev N. Nat Communication. 2024 Jun 14;15(1):5109. (Oxiant Discovery AB)

2021

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.  Nordström E, Eriksson F, Sigvardson J, Johannesson M, Kasrayan A, Jones-Kostalla M, Appelkvist P, Söderberg L, Nygren P, Blom M, Rachalski A, Nordenankar K, Zachrisson O, Amandius E, Osswald G, Moge M, Ingelsson M, Bergström J, Lannfelt L, Möller C, Giorgetti M, Fälting J.  Neurobiol Disease. 2021 Dec:161:105543. (BioArctic)

A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia. Lietzau G, Ntika S, Pintana H, Tracy L, Klein T, Nyström T, Darsalia V, Patrone C, Krizhanovskii C. Cell Mol Neurobiology.  2022 Aug;42(6):1995-2002.  (Uppsala University, Södertälje Hospital)

2018

Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-β signaling.  Lund H, Pieber M, Parsa R, Grommisch D, Ewing E, Kular L, Han J, Zhu K, Nijssen J, Hedlund E, Needhamsen M, Ruhrmann S, Ortlieb A, Guerreiro-Cacais A, Berglund R, Forteza MJ, Ketelhuth DJF, Butovsky O, Jagodic M, Zhang XM, Harris RA. Nat Immunology. 2018 May;19(5):1-7. (The Karolinska Institute)

Co-Authored Conference Abstracts

2025

Identification and Preclinical characterization of PET Tracers for Imaging ALPHA-Synuclein Aggregates in Parkinson's Disease and Multiple System Atrophy.   Manolo Mugnaini, Stella Vukelic, Gero Fink, Simone Benninghoff, Simon Seifarth, Alice Grill, Simon M. Spohr, Willi Amberg, Sandra Biesinger, Carmelina Petrungaro, Srirajan Vaidyanathan, Aimee Reed, Dan Sunnemark, Helen Jongsma Wallin, Peter Bosch, Nadine Ruderisch, Hollie Sanders, Caitlin Commins, Ji-Quan Wang, David Reuter, Ann Tovcimak, Martin Voorbach, Yuchuan Zhuang, Kyle Wilcox, Dustin Wooten, Marc Skaddan, Sjoerd Finnema, Tammy Dellovade, Miroslav Cik, Rob Comley, Frauke Pohlki, Stefan Barghorn. ADPD Conference (Abbvie)

​

Identification of Novel and Highly Selective Alpha-synuclein Ligands for PET Tracer Development 

Vukelic S, Fink G, Mugnaini M, Benninghoff S, Seifarth S, Grill A, Spohr S, Amberg W, Biesinger S, Petrungaro C, Vaidyanathan S, Reed A, Sunnemark D, Jongsma Wallin H, Bosch P, Ruderisch N, Sanders H, Commins C, Wang JQ, Reuter D, Tovcimak A, Voorbach M, Zhuang Y, Wilcox K, Wooten D, Skaddan M, Finnema S,  Dellovade T, Cik M, Comley R, Pohlki F, Barghorn S.  ADPD Conference (Abbvie)

 

Development and In Vitro Characterization of [3H]GMC-058 as Radioligand for Imaging Parkinsonian-Related Proteinopathies.  Andrea Varrone, Vasco C. Sousa, Manolo Mugnaini, Sandra Biesinger, Gunnar Nordvall, Lee Kingston, Ileana Guzzetti, Charles S. Elmore, Dan Sunnemark, Dinahlee Saturnino Guarino, Sjoerd J. Finnema and Magnus Schou. ADPD Conference (The Karolinska Institute, Abbvie, AstraZeneca)

​

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies. 

Olof Zachrisson, Malin Johannesson, Linda Söderberg, Fredrik Eriksson, Dan Sunnemark, Eva Nordström, My Björklund, Emily B. Button, Tomas Odergren, Christer Möller, Gunilla Osswald, Lars Lannfelt, & Johanna Fälting. ADPD Conference (Bioarctic)

 

Discovery and Preclinical Characterization of PET Tracers for Imaging Alpha-Synuclein Aggregates in the Human Brain.  Manolo Mugnaini, Stella Vukelic, Gero Fink, Martin Voorbach, Yuchuan Zhuang, Simone Benninghoff,Simon Seifarth, Alice Grill, Simon M Spohr, Willi Amberg, Carmelina Petrungaro, Srirajan Vaidyanathan,Aimee Reed, Dan Sunnemark, Helen Jongsma Wallin, Ji-Quan Wang, Bao Ying Chen, Dustin Wooten,Marc B Skaddan, Tammy Dellovade, Miroslav Cik, Rob Comley, Frauke Pohlki, Sjoerd J Finnema.  EANM Conference (Abbvie)

​

Identification and Preclinical characterization of PET Tracers for Imaging ALPHA-Synuclein Accregates in Parkinson's Disease and Multiple System Atrophy. Manolo Mugnaini, Stella Vukelic, Gero Fink, Simone Benninghoff, Simon Seifarth, Alice Grill, Simon M. Spohr, Willi Amberg, Sandra Biesinger, Carmelina Petrungaro, Srirajan Vaidyanathan, Aimee Reed, Dan Sunnemark, Helen Jongsma Wallin, Peter Bosch, Nadine Ruderisch, Hollie Sanders, Caitlin Commins, Ji-Quan Wang, David Reuter, Ann Tovcimak, Martin Voorbach, Yuchuan Zhuang, Kyle Wilcox, Dustin Wooten, Marc Skaddan, Sjoerd Finnema, Tammy Dellovade, Miroslav Cik, Rob Comley, Frauke Pohlki, Stefan Barghorn. Synuclein Meeting 2025 Cambridge UK  (Abbvie)

​

2024

Increased levels of 12 kDa C-terminal ApoE fragments in AD brain.  Sahlin C, Mattsson C, Kasrayan A, Hagiwara H, Kanatsu K, Andersson S, Sunnemark D, Fabre S, Lannfelt L, Möller C and Fälting J. ADPD Conference (BioArctic and Eisai)

Exidavnemab offers opportunities as a potential disease modifying ... Fälting J, Eriksson F, Nordström E, Söderberg L, Johannesson M, Zachrisson O, Appelkvist P, Möller C, Osswald G, Björklund M, Odergren T, Boström E, Button E, Sunnemark D. Congress International Parkinson and Movement Disorder Society (BioArctic)

​​​

2021

Elevated levels of soluble Amyloid beta...  Odergren T, Johannesson M, Sahlin C, Söderberg L, Basun H, Fälting J, Möller C, Zachrisson O, Sunnemark D, Svensson A, Lannfelt L.  ADPD Conference (BioArctic)

​

​

​

Key Conference Abstracts Supported by Our Platform

High-impact presentations utilizing data generated by Offspring Biosciences

​

2025
LECANEMAB DEMONSTRATES HIGHLY SELECTIVE BINDING TO AβPROTOFIBRILS ISOLATED FROM ALZHEIMER’S DISEASE BRAINS.  Johannesson M, Söderberg L, Zachrisson O] Olof Zachrisson, Nicolas Fritz, Helen Kylefjord, Eleni Gkanatsiou, Emily Button, Anne-Sophie Svensson, Charlotte Sahlin, Adeline Rachalski, Patrik Nygren, Gunilla Osswald, Lars Lannfelt , Christer Möller.  ADPD Conference (BioArctic)

 

2024

CHARACTERIZATION OF AMYLOID-BETA SPECIES IN ALZHEIMER’S DISEASE BRAIN AND THE UNIQUE BINDINGPROPERTIES OF LECANEMAB. Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou, Patrik Nygren, Emily Button, Anne-Sophie Svensson, Nicolas Fritz, Adeline Rachalski, Olof Zachrisson, Gunilla Osswald, Lars Lannfelt , Christer Möller.  BioArctic

​

2023

Lecanemab, an Aβ protofibril selective antibody, its mechanism of ... Lannfelt L.

ADPD conference (BioArctic) 

​

​

​

​

​

​

​

bottom of page